GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Crescita Therapeutics Inc (TSX:CTX) » Definitions » Cyclically Adjusted PB Ratio

Crescita Therapeutics (TSX:CTX) Cyclically Adjusted PB Ratio : 0.48 (As of Jan. 19, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Crescita Therapeutics Cyclically Adjusted PB Ratio?

As of today (2025-01-19), Crescita Therapeutics's current share price is C$0.58. Crescita Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 was C$1.22. Crescita Therapeutics's Cyclically Adjusted PB Ratio for today is 0.48.

The historical rank and industry rank for Crescita Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

TSX:CTX' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.45   Med: 0.48   Max: 0.52
Current: 0.48

During the past years, Crescita Therapeutics's highest Cyclically Adjusted PB Ratio was 0.52. The lowest was 0.45. And the median was 0.48.

TSX:CTX's Cyclically Adjusted PB Ratio is ranked better than
87.96% of 656 companies
in the Drug Manufacturers industry
Industry Median: 2.11 vs TSX:CTX: 0.48

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Crescita Therapeutics's adjusted book value per share data for the three months ended in Sep. 2024 was C$0.837. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is C$1.22 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Crescita Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Crescita Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crescita Therapeutics Cyclically Adjusted PB Ratio Chart

Crescita Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Crescita Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.49

Competitive Comparison of Crescita Therapeutics's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Crescita Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Crescita Therapeutics's Cyclically Adjusted PB Ratio falls into.



Crescita Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Crescita Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.58/1.22
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescita Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Crescita Therapeutics's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book=Book Value per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0.837/127.2847*127.2847
=0.837

Current CPI (Sep. 2024) = 127.2847.

Crescita Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201412 -0.200 98.367 -0.259
201503 0.000 99.789 0.000
201506 0.000 100.500 0.000
201509 0.000 100.421 0.000
201512 -0.280 99.947 -0.357
201603 2.542 101.054 3.202
201606 2.290 102.002 2.858
201609 2.048 101.765 2.562
201612 1.653 101.449 2.074
201703 1.453 102.634 1.802
201706 1.488 103.029 1.838
201709 1.454 103.345 1.791
201712 0.895 103.345 1.102
201803 0.774 105.004 0.938
201806 0.745 105.557 0.898
201809 0.765 105.636 0.922
201812 0.904 105.399 1.092
201903 0.921 106.979 1.096
201906 1.031 107.690 1.219
201909 1.035 107.611 1.224
201912 1.018 107.769 1.202
202003 0.998 107.927 1.177
202006 0.850 108.401 0.998
202009 1.055 108.164 1.241
202012 1.023 108.559 1.199
202103 1.005 110.298 1.160
202106 0.973 111.720 1.109
202109 0.926 112.905 1.044
202112 0.978 113.774 1.094
202203 0.958 117.646 1.036
202206 0.960 120.806 1.011
202209 0.975 120.648 1.029
202212 1.037 120.964 1.091
202303 1.025 122.702 1.063
202306 1.013 124.203 1.038
202309 0.956 125.230 0.972
202312 0.943 125.072 0.960
202403 0.928 126.258 0.936
202406 0.886 127.522 0.884
202409 0.837 127.285 0.837

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Crescita Therapeutics  (TSX:CTX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Crescita Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Crescita Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Crescita Therapeutics Business Description

Traded in Other Exchanges
Address
2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3
Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada.
Executives
Daniel Chicoine Director, Senior Officer
Jose Darocha Director, Senior Officer
Serge Verreault Senior Officer
Anthony Edward Dobranowski Director
Knight Therapeutics Inc. 10% Security Holder

Crescita Therapeutics Headlines

No Headlines